Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 33,196 | 33,144 | 29,725 | 25,306 | 22,073 |
| Cost of Goods | 5,319 | 6,291 | 5,260 | 4,810 | 6,273 |
| Gross Profit | 27,877 | 26,853 | 24,465 | 20,496 | 15,800 |
| Operating Expenses | 41,473 | 42,314 | 43,505 | 40,222 | 45,147 |
| Operating Income | -13,277 | -15,170 | -18,780 | -18,916 | -29,074 |
| Interest Expense | 6,216 | 3,144 | 3,989 | 3,448 | 3,521 |
| Other Income | 2,659 | 5,046 | 599 | -4,160 | -1,527 |
| Pre-tax Income | -16,834 | -13,268 | -22,170 | -26,524 | -34,122 |
| Income Tax | N/A | -338 | -339 | -339 | -408 |
| Net Income Continuous | -16,834 | -12,930 | -21,831 | -26,185 | -33,714 |
| Net Income | $-16,834 | $-12,930 | $-21,831 | $-26,185 | $-33,714 |
| EPS Basic Total Ops | -0.12 | -0.10 | -0.16 | -0.19 | -0.25 |
| EPS Basic Continuous Ops | -0.12 | -0.09 | -0.16 | -0.19 | -0.25 |
| EPS Diluted Total Ops | -0.12 | -0.10 | -0.16 | -0.19 | -0.25 |
| EPS Diluted Continuous Ops | -0.12 | -0.09 | -0.16 | -0.19 | -0.25 |
| EBITDA(a) | $-9,930 | $-11,219 | $-14,727 | $-15,725 | $-26,042 |